GSK has unveiled results from its late-stage trial evaluating its investigational five-in-one meningococcal vaccine that found it met all of the study's primary endpoints, according to a presentation of preliminary data during the European Society for Paediatric Infectious Diseases congress. There are currently no approved vaccines that provide simultaneous protection against all five Neisseria meningitides serogroups -- A, B, C, W and Y -- and in the US, a total of four injections, utilizing two separate vaccines, are needed for protection against all five serogroups.